Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-desacetyl metabolite, Org 9488, also exerts neuromuscular-blocking activity that. may became apparent after prolonged maintenance of relaxation with rapacuronium. In this study, the pharmacokinetic behavior (n = 7) of this metabolite and the pharmacokinetic/pharmacodynamic (PK/PD) relationship of rapacuronium (n = 10) and Org 9488 (n = 7) were investigated in humans. Similar protocols were used for three study groups regarding the anesthetic technique, blood and urine sampling, and pharmacokinetic and PK/PD analyses. The time course of action was measured mechanomyographically using the adductor pollicis muscle. The median clearance of rapacuro...
The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Or...
Patients with myasthenia gravis are more sensitive than healthy patients to nondepolarizing neuromus...
Several new steroidal non-depolarizing muscle relaxants have been synthesized and tested in humans r...
Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-de...
Neuromuscular blocking agents provide muscle relaxation for a great variety of surgical procedures w...
Rocuronium is a new non-depolarising agent with an intermediate time-course of neuromuscular blockin...
The existing human pharmacokinetic studies have been reviewed and compared with data derived from an...
BACKGROUND AND OBJECTIVE: This study clarifies the relationship between the neuromuscular blocking e...
Rapacuronium bromide (rapacuronium; ORG-9487) is a nondepolarising muscle relaxant (NMBA) with a low...
We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 942...
We have evaluated in 10 anaesthetized patients the time course of action, infusion requirements, rev...
The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Or...
We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 942...
The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Or...
Patients with myasthenia gravis are more sensitive than healthy patients to nondepolarizing neuromus...
Several new steroidal non-depolarizing muscle relaxants have been synthesized and tested in humans r...
Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-de...
Neuromuscular blocking agents provide muscle relaxation for a great variety of surgical procedures w...
Rocuronium is a new non-depolarising agent with an intermediate time-course of neuromuscular blockin...
The existing human pharmacokinetic studies have been reviewed and compared with data derived from an...
BACKGROUND AND OBJECTIVE: This study clarifies the relationship between the neuromuscular blocking e...
Rapacuronium bromide (rapacuronium; ORG-9487) is a nondepolarising muscle relaxant (NMBA) with a low...
We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 942...
We have evaluated in 10 anaesthetized patients the time course of action, infusion requirements, rev...
The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Or...
We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 942...
The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Or...
Patients with myasthenia gravis are more sensitive than healthy patients to nondepolarizing neuromus...
Several new steroidal non-depolarizing muscle relaxants have been synthesized and tested in humans r...